InFlectis BioScience: InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of Amyotrophic Lateral Sclerosis

(marketscreener.com) InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response , receives approval from the French Regulatory Authority ANSM to start a Phase 2 clinical trial evaluating IFB-088 for the treatment of Amyotrophic Lateral Sclerosis . The study is a ...https://www.marketscreener.com/news/latest/InFlectis-BioScience-Receives-Approval-from-French-Regulatory-Authority-to-Conduct-a-Phase-2-Clinica--37506322/?utm_medium=RSS&utm_content=20220110